Adverum Biotechnologies, Inc. (LON:0HA3)

Market Cap	68.70M
Revenue (ttm)	729.90K
Net Income (ttm)	-123.71M
Shares Out	n/a
EPS (ttm)	-5.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,692
Average Volume	17,805
Open	4.188
Previous Close	4.219
Day's Range	4.188 - 4.292
52-Week Range	1.799 - 8.410
Beta	n/a
RSI	50.30
Earnings Date	Nov 7, 2025

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 155
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HA3

Financial Performance

In 2024, Adverum Biotechnologies's revenue was $1.00 million, a decrease of -72.22% compared to the previous year's $3.60 million. Losses were -$130.93 million, 7.22% more than in 2023.

Financial numbers in USD